Cadrenal Therapeutics (CVKD) Cash from Operations (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Cash from Operations of 3000000.0 for Q1 2026, down 16.73% sequentially from 2569959.0 in Q4 2025, and up 35.47% YoY from 2214568.14 in Q1 2025.
Cadrenal Therapeutics (CVKD) Cash from Operations (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 3000000.0 in Q1 2026.
- Quarterly Cash from Operations rose 35.47% year-over-year to 3000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10952911.0 (down 7.7% YoY) and the FY2025 annual result came in at 12601666.0, down 71.28% from the prior year.
- Cash from Operations fell to 3000000.0 in Q1 2026 per CVKD's latest filing, from 2569959.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 43699.0 in Q1 2022 and troughed at 4648755.0 in Q1 2025.
- A 5-year average of 1629077.0 and a median of 1529244.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2026: Cash from Operations tumbled 3133.01% in 2023, then jumped 35.47% in 2026.
- Over 5 years, Cash from Operations stood at 290216.0 in 2022, then sank by 139.29% to 694445.0 in 2023, then slumped by 157.86% to 1790706.0 in 2024, then slumped by 43.52% to 2569959.0 in 2025, then slipped by 16.73% to 3000000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3000000.0, 2569959.0, and 2357150.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.23 Mn |
| Jun 30, 2026 | -2.23 Mn |
| Mar 31, 2026 | -3.00 Mn |
| Mar 31, 2026 | -3.00 Mn |
| Dec 31, 2025 | -2.57 Mn |
| Dec 31, 2025 | -2.57 Mn |
| Sep 30, 2025 | -2.36 Mn |
| Sep 30, 2025 | -2.36 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Mar 31, 2025 | -4.65 Mn |
| Mar 31, 2025 | -4.65 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Sep 30, 2024 | -2.20 Mn |
| Sep 30, 2024 | -2.20 Mn |
| Jun 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -1.53 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Mar 31, 2024 | -1.84 Mn |